Short Interest in Gossamer Bio, Inc. (NASDAQ:GOSS) Drops By 9.4%

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 6,300,000 shares, a decrease of 9.4% from the October 15th total of 6,950,000 shares. Based on an average trading volume of 810,000 shares, the short-interest ratio is presently 7.8 days.

Gossamer Bio Stock Down 2.7 %

Shares of NASDAQ GOSS traded down $0.02 during mid-day trading on Monday, hitting $0.72. The company had a trading volume of 597,580 shares, compared to its average volume of 1,430,347. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a 50-day simple moving average of $0.93 and a two-hundred day simple moving average of $0.87. The company has a market capitalization of $163.17 million, a PE ratio of -2.29 and a beta of 1.96. Gossamer Bio has a one year low of $0.50 and a one year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, equities analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on GOSS. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.20.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. SG Americas Securities LLC bought a new position in shares of Gossamer Bio in the 1st quarter valued at about $34,000. US Bancorp DE bought a new position in Gossamer Bio during the third quarter worth about $39,000. Choreo LLC acquired a new position in Gossamer Bio during the second quarter worth approximately $46,000. GSA Capital Partners LLP bought a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $67,000. Finally, Algert Global LLC bought a new position in Gossamer Bio during the second quarter worth $75,000. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.